123 related articles for article (PubMed ID: 23624021)
1. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
2. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD.
Praschberger M; Cornelius C; Schitegg M; Goldenberg H; Scheiber-Mojdehkar B; Sturm B
Pharm Dev Technol; 2015 Mar; 20(2):176-82. PubMed ID: 24219061
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical and toxicological characterization of a new generic iron sucrose preparation.
Meier T; Schropp P; Pater C; Leoni AL; Khov-Tran VV; Elford P
Arzneimittelforschung; 2011; 61(2):112-9. PubMed ID: 21428246
[TBL] [Abstract][Full Text] [Related]
6. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Inflamm Allergy Drug Targets; 2012 Feb; 11(1):66-78. PubMed ID: 22309085
[TBL] [Abstract][Full Text] [Related]
7. Comparison of early gastrointestinal tract and liver toxicity of the originator iron polymaltose complex (IPC) and an IPC similar preparation in non-anemic rats.
Toblli JE; Cao G; Angerosa M
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):573-83. PubMed ID: 22578204
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
9. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
[TBL] [Abstract][Full Text] [Related]
10. New rat models of iron sucrose-induced iron overload.
Vu'o'ng Lê B; Khorsi-Cauet H; Villegier AS; Bach V; Gay-Quéheillard J
Exp Biol Med (Maywood); 2011 Jul; 236(7):790-9. PubMed ID: 21685238
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia*.
Heming N; Lettéron P; Driss F; Millot S; El Benna J; Tourret J; Denamur E; Montravers P; Beaumont C; Lasocki S
Crit Care Med; 2012 Jul; 40(7):2141-8. PubMed ID: 22564959
[TBL] [Abstract][Full Text] [Related]
12. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
[TBL] [Abstract][Full Text] [Related]
13. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator.
Stein J; Dignass A; Chow KU
Curr Med Res Opin; 2012 Feb; 28(2):241-3. PubMed ID: 22181342
[TBL] [Abstract][Full Text] [Related]
14. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
[TBL] [Abstract][Full Text] [Related]
16. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
18. Is intravenous iron sucrose the treatment of choice for pregnant anemic women?
Devasenapathy N; Neogi SB; Zodpey S
J Obstet Gynaecol Res; 2013 Mar; 39(3):619-26. PubMed ID: 23167561
[TBL] [Abstract][Full Text] [Related]
19. Treatment of childhood-onset restless legs syndrome and periodic limb movement disorder using intravenous iron sucrose.
Grim K; Lee B; Sung AY; Kotagal S
Sleep Med; 2013 Nov; 14(11):1100-4. PubMed ID: 23993871
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]